Second-generation antidepressants (SGAs) are antidepressants that, unlike their first-generation counterparts, are significantly safer in cases of overdose and produce less prominent side effects. Examples include: NaSSAs, NDRIs, NRIs, RIMAs (like moclobemide), SARIs, SNRIs, SSRIs and certain TCAs. Of them bupropion (not licensed in Australia for this use), citalopram, escitalopram and sertraline tend to cause the fewest patients discontinuing them in clinical trials due to side effects. Whereas of these agents escitalopram and sertraline have demonstrated superior effectiveness, but as explained here the differences between these agents and other antidepressants as far as their effectiveness is small at best (usually so small that to see one patient benefit from one over another you would have to give like 20 patients the drug).
List of agentsEdit
- NCBI Bookshelf provides free book resources on this topic.
- PubMed provides review articles from the past five years (limit to free review articles or to systematic reviews)
- The TRIP database provides clinical publications about evidence-based medicine.
- ↑ Cipriani, A; Furukawa, TA; Salanti, G; Geddes, JR; Higgins, JP; Churchill, R; Watanabe, N; Nakagawa, A; Omori, IM; McGuire, H; Tansella, M; Barbui, C (February 2009). "Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis." (PDF). Lancet 373 (9665): 746–58. PMID 19185342. doi:10.1016/S0140-6736(09)60046-5.